FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105848402> ?p ?o ?g. }

• W2105848402 endingPage "1113" @default.
• W2105848402 startingPage "1105" @default.
• W2105848402 abstract "Background. Two antibiotic regimens are used commonly in Thailand for the initial treatment of severe melioidosis: ceftazidime in combination with trimethoprim-sulfamethoxazole (TMP-SMX) and ceftazidime monotherapy. It is not known whether TMP-SMX provides an additional benefit. Methods. Two prospective, randomized trials that compared these regimens for patients presenting with acute severe melioidosis were started independently at tertiary care hospitals in Ubon Ratchathani and Khon Kaen (in northeastern Thailand), and the results were analyzed together as a prospective, individual-patient data meta-analysis. The primary end point was in-hospital mortality rate. Results. The in-hospital mortality rate among all enrolled patients (n = 449) was not significantly different between those randomized to ceftazidime alone (25.1%; 56 of 223 subjects) and those randomized to ceftazidime with TMP-SMX (26.6%; 60 of 226 subjects; odds ratio [OR], 1.08; 95% confidence interval [CI], 0.7–1.7; stratified P = .73). Of the 241 patients with culture-confirmed melioidosis, 51 (21.2%) died. Of these 241 patients, 31 (12.9%) died ⩾48 h after the time of study entry. Among patients with melioidosis, there was no difference in death rate between the 2 treatment groups for either all deaths (OR, 0.88; 95% CI, 0.48–1.6; stratified P = .70) or for deaths that occurred ⩾48 h after hospital admission (OR, 0.88; 95% CI, 0.41–1.9; stratified P = .73). Conditional logistic regression analysis revealed that bacteremia, respiratory failure, and renal failure were independently associated with death and treatment failure. Drug regimens were not associated with death or treatment failure in this model. Conclusion. We conclude that the addition of TMP-SMX to ceftazidime therapy during initial treatment of severe melioidosis does not reduce the acute mortality rate." @default.
• W2105848402 created "2016-06-24" @default.
• W2105848402 creator A5012084972 @default.
• W2105848402 creator A5013453998 @default.
• W2105848402 creator A5014626556 @default.
• W2105848402 creator A5024508211 @default.
• W2105848402 creator A5031956134 @default.
• W2105848402 creator A5034097318 @default.
• W2105848402 creator A5042629578 @default.
• W2105848402 creator A5058967121 @default.
• W2105848402 creator A5065993329 @default.
• W2105848402 creator A5066695072 @default.
• W2105848402 creator A5067547071 @default.
• W2105848402 creator A5070410197 @default.
• W2105848402 creator A5083740562 @default.
• W2105848402 creator A5084217335 @default.
• W2105848402 creator A5086465104 @default.
• W2105848402 date "2005-10-15" @default.
• W2105848402 modified "2023-10-18" @default.
• W2105848402 title "Two Randomized Controlled Trials of Ceftazidime Alone versus Ceftazidime in Combination with Trimethoprim-Sulfamethoxazole for the Treatment of Severe Melioidosis" @default.
• W2105848402 cites W1968142908 @default.
• W2105848402 cites W1980392406 @default.
• W2105848402 cites W1999279226 @default.
• W2105848402 cites W2004912862 @default.
• W2105848402 cites W2035904942 @default.
• W2105848402 cites W2083291804 @default.
• W2105848402 cites W2092496758 @default.
• W2105848402 cites W2101891378 @default.
• W2105848402 cites W2143061164 @default.
• W2105848402 doi "https://doi.org/10.1086/444456" @default.
• W2105848402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16163628" @default.
• W2105848402 hasPublicationYear "2005" @default.
• W2105848402 type Work @default.
• W2105848402 sameAs 2105848402 @default.
• W2105848402 citedByCount "72" @default.
• W2105848402 countsByYear W21058484022012 @default.
• W2105848402 countsByYear W21058484022014 @default.
• W2105848402 countsByYear W21058484022015 @default.
• W2105848402 countsByYear W21058484022016 @default.
• W2105848402 countsByYear W21058484022017 @default.
• W2105848402 countsByYear W21058484022018 @default.
• W2105848402 countsByYear W21058484022019 @default.
• W2105848402 countsByYear W21058484022020 @default.
• W2105848402 countsByYear W21058484022021 @default.
• W2105848402 countsByYear W21058484022022 @default.
• W2105848402 countsByYear W21058484022023 @default.
• W2105848402 crossrefType "journal-article" @default.
• W2105848402 hasAuthorship W2105848402A5012084972 @default.
• W2105848402 hasAuthorship W2105848402A5013453998 @default.
• W2105848402 hasAuthorship W2105848402A5014626556 @default.
• W2105848402 hasAuthorship W2105848402A5024508211 @default.
• W2105848402 hasAuthorship W2105848402A5031956134 @default.
• W2105848402 hasAuthorship W2105848402A5034097318 @default.
• W2105848402 hasAuthorship W2105848402A5042629578 @default.
• W2105848402 hasAuthorship W2105848402A5058967121 @default.
• W2105848402 hasAuthorship W2105848402A5065993329 @default.
• W2105848402 hasAuthorship W2105848402A5066695072 @default.
• W2105848402 hasAuthorship W2105848402A5067547071 @default.
• W2105848402 hasAuthorship W2105848402A5070410197 @default.
• W2105848402 hasAuthorship W2105848402A5083740562 @default.
• W2105848402 hasAuthorship W2105848402A5084217335 @default.
• W2105848402 hasAuthorship W2105848402A5086465104 @default.
• W2105848402 hasBestOaLocation W21058484021 @default.
• W2105848402 hasConcept C126322002 @default.
• W2105848402 hasConcept C141071460 @default.
• W2105848402 hasConcept C142724271 @default.
• W2105848402 hasConcept C156957248 @default.
• W2105848402 hasConcept C168563851 @default.
• W2105848402 hasConcept C188816634 @default.
• W2105848402 hasConcept C2776968632 @default.
• W2105848402 hasConcept C2777637488 @default.
• W2105848402 hasConcept C2779110727 @default.
• W2105848402 hasConcept C2779425571 @default.
• W2105848402 hasConcept C2779443120 @default.
• W2105848402 hasConcept C2779775996 @default.
• W2105848402 hasConcept C2780728791 @default.
• W2105848402 hasConcept C44249647 @default.
• W2105848402 hasConcept C501593827 @default.
• W2105848402 hasConcept C523546767 @default.
• W2105848402 hasConcept C54355233 @default.
• W2105848402 hasConcept C71924100 @default.
• W2105848402 hasConcept C86803240 @default.
• W2105848402 hasConcept C89423630 @default.
• W2105848402 hasConceptScore W2105848402C126322002 @default.
• W2105848402 hasConceptScore W2105848402C141071460 @default.
• W2105848402 hasConceptScore W2105848402C142724271 @default.
• W2105848402 hasConceptScore W2105848402C156957248 @default.
• W2105848402 hasConceptScore W2105848402C168563851 @default.
• W2105848402 hasConceptScore W2105848402C188816634 @default.
• W2105848402 hasConceptScore W2105848402C2776968632 @default.
• W2105848402 hasConceptScore W2105848402C2777637488 @default.
• W2105848402 hasConceptScore W2105848402C2779110727 @default.
• W2105848402 hasConceptScore W2105848402C2779425571 @default.
• W2105848402 hasConceptScore W2105848402C2779443120 @default.
• W2105848402 hasConceptScore W2105848402C2779775996 @default.
• W2105848402 hasConceptScore W2105848402C2780728791 @default.
• W2105848402 hasConceptScore W2105848402C44249647 @default.
• W2105848402 hasConceptScore W2105848402C501593827 @default.

• next